Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer. Wang C, Li K, Huang R, Wan S, et al. BMC Cancer 2025;25:271.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang C, Li K, Huang R, Wan S, et al. Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer. BMC Cancer 2025;25:271.
PMID: 39955518